This was a longitudinal study including Swedish BioFINDER-2 (enrollment 2017-2022) andreplication in 2 independent cohorts, the Knight Alzheimer Disease Research Center(Knight ADRC; enrollment 1988 and 2019) and Swedish BioFINDER-1 (enrollment 2009-2015).Included for analysis was a convenience sample of CU individuals with baseline plasmaphosphorylated tau 217 (p-tau217) and Aβ42/40 assessments and Aβ assessmentswith positron emission tomography (Aβ-PET) or cerebrospinal fluid (CSF)Aβ42/40. The gene discussed is MAPT; the disease is Alzheimer disease.